Cancer Prevention Pharmaceuticals, which is developing treatments for colorectal cancer risk factors, announced terms for its IPO on Wednesday.
The Tucson, AZ-based company plans to raise $25 million by offering 1.9 million shares at a price range of $12 to $14. Insiders intend to purchase $5 million worth of shares in the offering. At the midpoint of the proposed range, Cancer Prevention Pharmaceuticals would command a fully diluted market value of $110 million.
Cancer Prevention Pharmaceuticals was founded in 2009 and booked $4 million in sales for the 12 months ended December 31, 2015. It plans to list on the NYSE under the symbol CPP. Aegis Capital Corp. and Maxim Group LLC are the joint bookrunners on the deal. Pricing details were not disclosed.
The article Clinical-stage biotech Cancer Prevention sets terms for $25 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
